Trials / Unknown
UnknownNCT03652896
Anatomy-based Resection or Margin-based Resection for Hepatocellular Carcinoma
Anatomy-based Resection or Margin-based Resection for Hepatocellular Carcinoma: A Randomized Controlled Trial
- Status
- Unknown
- Phase
- N/A
- Study type
- Interventional
- Enrollment
- 60 (estimated)
- Sponsor
- Huazhong University of Science and Technology · Academic / Other
- Sex
- All
- Age
- 17 Years – 65 Years
- Healthy volunteers
- Not accepted
Summary
Anatomical liver resection was widely accepted as first line curative therapy for hepatocellular carcinoma. However, number of retrospective clinical studies showed no priority of anatomical resection for hepatocellular, compared with non-anatomical resection. Surgical resection margin is a essential factor that may affect tumor prognosis. It is controversial whether adequate liver resection margin is associated with improved survival outcome in patients with hepatocellular. There was few prospective clinical trial to investigate whether anatomical liver resection is superior to non-anatomical resection or liver resection with adequate margin is superior to that with inadequate margin. This prospective clinical trial aims at fix these issues.
Detailed description
In the anatomical liver resection group, liver segmentectomy or lobectomy is performed to insure curative resection (R0 resection). The region of liver resected is based on the anatomy or portal vein and hepatic vein. The liver pedicle of the tumor located lobe is exposed and dissected, which is principle to perform anatomical liver resection. In the non-anatomical liver resection group, the liver parenchyma transection is around 0-2 cm from the tumor margin, according to tumor size and location.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| PROCEDURE | anatomical liver resection | Liver resection is performed to achieve R0 resection for patients with appropriate BCLC staging, indocyanine green retention rate, Child-pugh grading and adequate liver remnant. |
Timeline
- Start date
- 2019-01-01
- Primary completion
- 2021-12-30
- Completion
- 2023-12-30
- First posted
- 2018-08-29
- Last updated
- 2018-08-29
Locations
1 site across 1 country: China
Source: ClinicalTrials.gov record NCT03652896. Inclusion in this directory is not an endorsement.